A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates
Open Access
- 16 July 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1419634
Abstract
Herpes zoster (HZ), also known as shingles, remains a significant global health issue and most commonly seen in elderly individuals with an early exposure history to varicella-zoster virus (VZV). Currently, the licensed vaccine Shingrix, which comprises a recombinant VZV glycoprotein E (gE) formulated with a potent adjuvant AS01B, is the most effective shingles vaccine on the market. However, undesired reactogenicity and increasing global demand causing vaccine shortage, prompting the development of novel shingles vaccines. Here, we developed novel vaccine candidates utilising multiple nanoparticle (NP) platforms to display the recombinant gE antigen, formulated in an MF59-biosimilar adjuvant. In naïve mice, all tested NP vaccines induced higher humoral and cellular immune responses than Shingrix, among which, the gEM candidate induced the highest cellular response. In live attenuated VZV (VZV LAV)-primed mouse and rhesus macaque models, the gEM candidate elicited superior cell-mediated immunity (CMI) over Shingrix. Collectively, we demonstrated that NP technology remains a suitable tool for developing shingles vaccine, and the reported gEM construct is a highly promising candidate in the next-generation shingles vaccine development.Keywords
This publication has 72 references indexed in Scilit:
- Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trialeClinicalMedicine, 2023
- Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2Journal of Microbiology, 2022
- Meta-Regression of Herpes Zoster Incidence WorldwideInfectious Diseases and Therapy, 2021
- Sensitivity and specificity of different antibody tests for detecting varicella-zoster virusJournal of Infection and Chemotherapy, 2020
- Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial VirusCell, 2019
- Recent advances in steroidal saponins biosynthesis and in vitro productionPlanta, 2018
- Structure of AP205 Coat Protein Reveals Circular Permutation in ssRNA BacteriophagesJournal of Molecular Biology, 2016
- Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding SiteCell, 2015
- Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigensClinical Immunology, 2014
- Immune Responses to Varicella-Zoster in the AgedArchives of internal medicine (1960), 1982